What this is
Single filing record
This page shows the rows from one Form 4 filing as reported to the SEC.
Big buy
Ra Capital Nexus Fund III, LP: large open-market buy of BCAX
$35.2M open-market purchase by Ra Capital Nexus Fund III, LP, Director at Bicara Therapeutics Inc, filed March 2, 2026. Learn more
Feed status Last SEC check:Loading Last Filing: Loading
View BCAX
Access Free feed
Quick read What does this view show?
Why it matters
Read the SEC filing
The original SEC document is the source record. Always verify before drawing conclusions.
How to read it
Role, size, timing
Insider activity carries more weight from senior officers, large dollar values, and clustered timing.
Stacked feeds
Key insider views at a glance
Big BuyBCAX
$22.92+4.42% today
Ra Capital Nexus Fund III, LP · Director at Bicara Therapeutics Inc
$35.2M
Ra Capital Nexus Fund III, LP bought $35.2M of BCAX (Bicara Therapeutics Inc).
Insider purchase
Transaction details
Ra Capital Nexus Fund III, LP, a Director, reported a $35.2M open-market purchase equal to 2.5% of BCAX's market cap.
Ra Capital Nexus Fund III, LP (Director) bought 2,200,000 shares of BCAX, Bicara Therapeutics Inc, Healthcare ($1.43B market cap), at $15.9999 per share on February 26, 2026 for a total of $35.2M (2.5% of the market cap).
Ra Capital Nexus Fund III, LP
Director
Purchase value$35.2M
Shares purchased2,200,000
Price per share$15.9999 per share
- % of market cap
- 2.5%
- Trade date
- February 26, 2026
- Filed
- March 2, 2026
- Filing delay
- 4 days
Permalink https://bluecollarpicks.com/insider-trading/BCAX/buy/767824
Market context
BCAX market snapshot
Current price$22.92
1-day change+4.42%
Market cap$1.43B
SectorHealthcare
Next earningsAugust 10, 2026
$22.92
Current price$22.92
Analyst target$31.46 (+45.1%)
Last enriched June 20, 2026 at 8:49 AM EDT.
Filings
Recent insider trades
Status Loading
Latest visible filing loading.
Public Form 4 filings, normalized for cleaner scanning. What do these codes mean?
| Ticker | Type & Role | Value | |
|---|---|---|---|
| This filing | Cluster Buy Director | $35.2M | |
Grant Director | $0 | ||
Exercise and Hold CFO | $34.9K | ||
Sell CFO | $211.6K | ||
Exercise and Hold CFO | Not reported | ||
Exercise and Hold CEO | $56.8K | ||
Exercise and Hold CEO | Not reported | ||
Sell CEO | $354.1K | ||
Exercise and Hold CEO | $38.6K | ||
Exercise and Hold CEO | $28.2K | ||
Exercise and Hold CEO | Not reported | ||
Exercise and Hold CEO | Not reported | ||
Exercise and Hold CEO | $36.5K | ||
Exercise and Hold CEO | Not reported | ||
Sell President | $103.5K | ||
Exercise and Hold President | $30.3K | ||
Sell President | $184.1K | ||
Exercise and Hold President | Not reported | ||
| $88.5K | |||
| $30.3K | |||
| $157.3K | |||
| Not reported | |||
| $139.3K | |||
| $704.7K | |||
| Not reported | |||
| $14.5K | |||
| $71.6K | |||
| Not reported | |||
| $6.8K | |||
| $33.5K | |||
| Not reported | |||
| $49.3K | |||
| Not reported | |||
| $10K | |||
| $81.7K | |||
| $48.9K | |||
| $234.2K | |||
| Not reported | |||
| $11.2K | |||
| $54.1K | |||
| Not reported | |||
| $23.6K | |||
| Not reported | |||
| $27.7K | |||
| Not reported | |||
| $246.9K | |||
| $61.8K | |||
| $301.9K | |||
| Not reported | |||
| $758 | |||
| $3.7K | |||
Cluster Buy Director
Grant Director
$56.8K
Exercise and Hold CEO
Not reported
Exercise and Hold CEO
$354.1K
Sell CEO
$38.6K
Exercise and Hold CEO
$28.2K
Exercise and Hold CEO
Not reported
Exercise and Hold CEO
Not reported
Exercise and Hold CEO
$36.5K
Exercise and Hold CEO
Not reported
Exercise and Hold CEO
$103.5K
Sell President
$30.3K
Exercise and Hold President
$184.1K
Sell President
Not reported
Exercise and Hold President
$88.5K
$30.3K
$157.3K
Not reported
$139.3K
$704.7K
Not reported
$14.5K
$71.6K
Not reported
$6.8K
$33.5K
Not reported
$49.3K
Not reported
$10K
$81.7K
$48.9K
$234.2K
Not reported
$61.8K
$301.9K
Not reported
$758
$3.7K
Cluster detail
Cluster members
Ticker context
Ticker summary
Recent insider activity for this company.
Insider detail
Insider activity
Recent transactions grouped by reporting owner.
Filters
Filters
Weekly recap
Get the easier version in your inbox.
Start with the free weekly recap. Upgrade later if you want the paid daily brief.
Free weekly recap. No login required. Unsubscribe any time.
Method Public Form 4 filings, normalized for cleaner scanning. Filtered rows stay available in All Form 4 Filings and ticker history. Which view should I use? →
Paid research tools
CSV exports are becoming a paid feature.
Join the waitlist for founding-member access to CSV exports, saved screens, and premium download tools when they open.